Target intelligence / Profile preview

HIV-1 envelope glycoprotein gp41 (membrane fusion domain) (gp41 (Env))

Target
gp41 (Env)
Molecular classification
Viral fusion protein, Class I fusion protein, Envelope glycoprotein
01

Overview

The envelope glycoprotein of HIV-1 facilitates fusion of viral and host cell membranes, a critical step for viral entry and infection. This glycoprotein is composed of a surface subunit (gp120), which binds to cellular CD4 and a coreceptor (CCR5 or CXCR4), and a transmembrane subunit (gp41), which mediates membrane fusion. Upon receptor engagement, gp41 undergoes dramatic conformational changes, forming a six-helix bundle that brings the viral and cellular membranes into proximity and catalyzes their merger. The fusion mechanism has been structurally elucidated, setting the stage for the development of peptide-based therapeutics, such as enfuvirtide, that block key steps in the fusion process. The membrane fusion activity is exclusive to enveloped viruses and remains a major target for anti-HIV drug development[1][2][3][6][7][8].

Other names
HIV EnvHIV envelope glycoproteingp41HIV-1 EnvHIV-1 gp41HIV fusion protein
02

Mechanism of action

Inhibition of six-helix bundle formation in gp41, preventing fusion of the viral and cellular membranes[7]. Stabilization of intermediate conformations that block further refolding of gp41 required for fusion[1].

03

Biological functions

Membrane fusionViral entryInfection establishmentHost cell membrane destabilization
04

Disease associations

Infection (HIV/AIDS)
05

Safety considerations

Injection-site reactions (for enfuvirtide)Potential for resistance via mutations in gp41Possible effects on calcium-dependent steps in fusion, affecting inhibitor potency[7]
06

Interacting drugs

Enfuvirtide (T20; Fuzeon)

1 more in the full profile.

07

Biomarkers

HIV-1 RNA viral load for efficacy monitoringNo direct patient stratification biomarker for fusion inhibitors

Beyond the preview

Go deeper on HIV-1 envelope glycoprotein gp41 (membrane fusion domain) (gp41 (Env)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 envelope glycoprotein gp41 (membrane fusion domain) (gp41 (Env)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call